Clinical study new short acting sulfanilamide (sulfacytine). Protocol 636-48.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy; D003596:Cytosine / Q000627:therapeutic use; D005260:Female; D006417:Hematuria / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011704:Pyelonephritis / Q000188:drug therapy; D013444:Sulfisoxazole / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy
D000892:Anti-Infective Agents, Urinary; D013449:Sulfonamides; D013444:Sulfisoxazole; D003596:Cytosine